A One-Shot Treatment for Breast Cancer
British researchers have demonstrated that a single, targeted dose of radiation in treating breast cancer can be just as effective as the prolonged course of radiotherapy that is commonly used to treat the disease.
British researchers have demonstrated that a single, targeted dose of radiation in treating breast cancer can be just as effective as the prolonged course of radiotherapy that is commonly used to treat the disease.
The researchers said the technique not only saves time and money, but dramatically reduces the chance of injury to a patient’s vital organs. –JCL
AS CHAOS UNFOLDS, FIND SOLID GROUND…The BBC:
A single dose of radiation during surgery is just as effective as a prolonged course of radiotherapy for breast cancer, a study suggests.
Doctors have tested the technique, which involves a single shot of radiotherapy to a tumour site, in more than 2,000 patients.
It could save the UK £15m a year, the researchers said.
Cancer Research UK said The Lancet study could have a “huge impact” for patients.
In this time of unprecedented challenges, independent journalism is more vital than ever. At Truthdig, we expose what power wants hidden and give you the clarity to make sense of it all.
Your donation helps ensure that truth telling continues.
Health & Wellness
The agency cites no new science but relies on an executive order about “restoring biological truth” in government.
Interview
A conversation with Meredith Broussard.
She was in her 20s when the book chronicling her addiction and depression was published, igniting a debate that lasted for much of her life.
It’s not just first responders who were harmed by fumes from the lower Manhattan attack, but workers, students and area residents.
Here's a sad bit of irony from the health news department: The type of cancer that's killing the majority of women in so-called developed nations can be quite preventable in some cases -- and it can come down to a matter of personal choice.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.